GRTS News and Press, Gritstone Oncology Inc. From 01/26/21

Gainers: Oxbridge Re (OXBR) +62%.Koss (KOSS) +60%.AIkido Pharma (AIKI) +51%.Vertex Energy (VTNR) +56%.Phunware (PHUN) +45%.Edesa Biotech (EDSA) +33%.CarParts.com (PRTS) +32%.Workhorse Group (WKHS) +30%.Orbital Energy (OEG) +27%.Vir Biotechnology (VIR) +27%.Losers: Express ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The Dow Jones and S&P 500 indexes fell slightly on Friday but clawed back from their worst losses, while the Nasdaq edged higher to another record clos...

Gritstone Oncology (NASDAQ: GRTS) started the week as a little-known player in the coronavirus vaccine space. Its shares were trading at less than $10 apiece, and the market value totaled well under $1 billion. And then, in a blink of an eye, all of that changed. Its shares -- and m...

With the price target unchanged at $8 per share, Baird lowers its recommendation on Gritstone Oncology (GRTS) to Underperform from Outperform, citing a ‘recent substantial upside’ in the stock despite ‘a myriad issues’ that the company’s COVID-19 vaccine dev...

Should Investors Consider These Top Biotech Stocks Now? 3 Making Moves Biotech stocks have become some of the hottest stocks on the market right now. Last year, coronavirus vaccine companies led the charge as the biotech industry outpaced the broader market. Over the past year, ...

Gritstone Oncology (GRTS) and Genevant Sciences, nucleic acid delivery company with world-class platforms and the industry's most robust and expansive lipid nanoparticle patent estate, inked a license agreement post which the former obtained a non-exclusive license to the latter's LNP technol...

— Deal provides nonexclusive access to Genevant’s leading LNP technology for use in Gritstone’s self-amplifying RNA COVID-19 vaccine program; NIH-sponsored Phase 1 clinical trial expected to initiate in 1Q21 — — Agreement is the second...

Gainers: [[PCTI]] +20.5%. [[GRTS]] +19.1%. [[NFLX]] +11.9%. [[CLFD]] +11.8%. [[BRMK]] +7.5%.Losers: [[ACRX]] -12.8%. [[PERI]] -8.3%. [[LAC]] -8.3%. [[DSS]] -8.2%. [[SYRS]] -7.7%. For further details see: PCTI, NFLX, ACRX and DSS among after-hours movers

Gainers: Aclaris Therapeutics (ACRS) +184%.Gritstone Oncology (GRTS) +111%.Gevo (GEVO) +76%.Senseonics (SENS) +72%.TransEnterix (TRXC) +62%.Dare Bioscience (DARE) +57%.ENDRA Life Sciences (NDRA) +41%.Pennsylvania Real Estate Investment Trust (PEI) +41%.Tenax Therapeutics (TENX)...

Shares of the clinical-stage biotech Gritstone Oncology (NASDAQ: GRTS) rose by as much as 44% in pre-market trading Tuesday morning. The drugmaker's stock is heating up today in response to an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to initia...